Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol 3350 + sodium sulfate + potassium sulfate + magnesium sulfate
- Development stage
- Approved
- Lead developer
- Sebela Pharmaceuticals
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
This drug is an osmotic laxative combination used for bowel cleansing prior to colonoscopy. It consists of two main components: a polyethylene glycol (PEG) 3350 electrolyte solution and a mixture of sulfate salts (sodium sulfate, potassium sulfate, and magnesium sulfate). The mechanism of action involves the creation of an osmotic gradient within the intestinal lumen; the non-absorbable PEG and poorly absorbed sulfate ions draw water into the colon, increasing the volume of the luminal contents and stimulating bowel movements. This combination was designed to provide effective colon cleansing with a lower volume of fluid compared to traditional 4-liter PEG-based preparations. It was developed by Braintree Laboratories and received FDA approval in 2013 under the brand name Suclear, though it was later discontinued from the market.
- Brand names
- Suclear
- Other names
- polyethylene glycol + sodium sulfate + potassium sulfate + magnesium sulfatePEG-3350 + sodium sulfate + potassium sulfate + magnesium sulfatePEG-Sulfate
Beyond the preview
Go deeper on polyethylene glycol 3350 + sodium sulfate + potassium sulfate + magnesium sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol 3350 + sodium sulfate + potassium sulfate + magnesium sulfate.